Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Other Non-Current Liabilities (2021 - 2025)

Historic Other Non-Current Liabilities for Ensysce Biosciences (ENSC) over the last 5 years, with Q3 2025 value amounting to $35.0.

  • Ensysce Biosciences' Other Non-Current Liabilities changed N/A to $35.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.0, marking a year-over-year change of. This contributed to the annual value of $10096.0 for FY2024, which is 6174.02% down from last year.
  • As of Q3 2025, Ensysce Biosciences' Other Non-Current Liabilities stood at $35.0.
  • In the past 5 years, Ensysce Biosciences' Other Non-Current Liabilities registered a high of $3.7 million during Q4 2021, and its lowest value of $35.0 during Q3 2025.
  • Its 5-year average for Other Non-Current Liabilities is $703182.0, with a median of $310346.0 in 2022.
  • Within the past 5 years, the most significant YoY rise in Ensysce Biosciences' Other Non-Current Liabilities was 4782.47% (2022), while the steepest drop was 9150.39% (2022).
  • Ensysce Biosciences' Other Non-Current Liabilities (Quarter) stood at $3.7 million in 2021, then tumbled by 91.5% to $310346.0 in 2022, then crashed by 91.5% to $26388.0 in 2023, then crashed by 61.74% to $10096.0 in 2024, then crashed by 99.65% to $35.0 in 2025.
  • Its Other Non-Current Liabilities stands at $35.0 for Q3 2025, versus $1033.0 for Q2 2025 and $130180.0 for Q1 2025.